{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:39:01Z","timestamp":1787027941642,"version":"build-2736575974"},"reference-count":23,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Direcci\u00f3n General de Investigaciones de la Universidad Santiago de Cali","award":["01-2025"],"award-info":[{"award-number":["01-2025"]}]},{"name":"Direcci\u00f3n General de Investigaciones de la Universidad Santiago de Cali","award":["DGI-445-621124-760"],"award-info":[{"award-number":["DGI-445-621124-760"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Cutaneous toxicities associated with CDK4\/6 inhibitors are uncommon but may affect treatment adherence. We present the case of a patient with advanced breast cancer who developed vitiligo-like lesions after initiating ribociclib, contributing to the growing evidence of this under-recognized adverse effect. Methods: We present the case of a 72-year-old woman diagnosed in 2007 with early-stage, luminal A, HER2-negative breast cancer, initially treated with surgery and tamoxifen. In 2022, she experienced locoregional recurrence with bone metastases. In January 2023, she began treatment with ribociclib plus letrozole. Two months later, she developed intense pruritus, xerosis, and paresthesia, followed by hypopigmented lesions on her face and upper extremities. Clinical evaluation, supported by photographs and a skin biopsy (led to a diagnosis of ribociclib-induced vitiligo. Management included dose adjustments to the ribociclib and dermatologic treatments, including topical corticosteroids, antihistamines, and short courses of oral prednisone. Results: By September 2024, her skin lesions had stabilized and her pruritus improved with a reduced dose of ribociclib (one tablet per day). However, the hypopigmented patches persisted, mainly on her face and extremities. Despite these cutaneous effects, she maintained an acceptable quality of life and continued effective oncologic treatment. Conclusions: This case highlights the importance of early recognition and management of ribociclib-related cutaneous toxicities. A multidisciplinary approach is essential to minimize adverse effects without compromising therapeutic efficacy. Further research into the dermatologic manifestations of targeted therapies is needed to optimize patient care.<\/jats:p>","DOI":"10.3390\/diseases13050158","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:37:13Z","timestamp":1747633033000},"page":"158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia"],"prefix":"10.3390","volume":"13","author":[{"given":"John Fernando","family":"Montenegro","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia"},{"name":"Grupo de Investigaci\u00f3n en Gen\u00e9tica, Fisiolog\u00eda y Metabolismo (GEFIME), Ciencias de la Salud Universidad Santiago de Cali, Cali 760035, Colombia"},{"name":"Programa de Especializaci\u00f3n en Medicina Interna, Facultad de Salud, Universidad Santiago de Cali, Cali 5183000, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Patricia","family":"Rivas-Tafurt","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Gen\u00e9tica, Fisiolog\u00eda y Metabolismo (GEFIME), Ciencias de la Salud Universidad Santiago de Cali, Cali 760035, Colombia"},{"name":"Programa de Especializaci\u00f3n en Medicina Interna, Facultad de Salud, Universidad Santiago de Cali, Cali 5183000, Colombia"},{"name":"Departamento de Investigaci\u00f3n y Educaci\u00f3n, Cl\u00ednica de Occidente S.A., Cali 760046, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinthia","family":"Vidal-Ca\u00f1as","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Diaz-Diaz","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Eduardo","family":"Bermudez","sequence":"additional","affiliation":[{"name":"Programa de Especializaci\u00f3n en Medicina Interna, Facultad de Salud, Universidad Santiago de Cali, Cali 5183000, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Florez","sequence":"additional","affiliation":[{"name":"Programa de Especializaci\u00f3n en Medicina Interna, Facultad de Salud, Universidad Santiago de Cali, Cali 5183000, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Felipe","family":"Bravo-Gustin","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-8725","authenticated-orcid":false,"given":"Yamil","family":"Liscano","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia"},{"name":"Programa de Especializaci\u00f3n en Medicina Interna, Facultad de Salud, Universidad Santiago de Cali, Cali 5183000, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: An Update on Pathophysiology and Treatment Options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.293.6.730","article-title":"New Insights and New Therapies in Vitiligo","volume":"293","author":"Grimes","year":"2005","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/JD9.0000000000000346","article-title":"An Extensive Review of Vitiligo-Associated Conditions","volume":"7","author":"Premkumar","year":"2023","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_4","first-page":"637","article-title":"Vitiligo: Recent Insights and New Therapeutic Approaches","volume":"147","author":"Lotti","year":"2012","journal-title":"G. Ital. Di Dermatol. E Venereol. Organo Uff. Soc. Ital. Di Dermatol. E Sifilogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like Lesions in Patients with Advanced Breast Cancer Treated with Cycline-Dependent Kinases 4 and 6 Inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sollena, P., Vasiliki, N., Kotteas, E., Stratigos, A.J., Fattore, D., Orlandi, A., Mannino, M., Di Pumpo, M., Fida, M., and Starace, M. (2023). Cyclin-Dependent Kinase 4\/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force \u201cDermatology for Cancer Patients\u201d International Study. Cancers, 15.","DOI":"10.3390\/cancers15143658"},{"key":"ref_7","first-page":"E01","article-title":"Cutaneous Adverse Events under New Clinical Therapies: Drug-Induced Vitiligo-like Depigmentation","volume":"7","author":"Ma","year":"2023","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/oncolo\/oyae004","article-title":"Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+\/HER2\u2212 Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication","volume":"29","author":"Borroni","year":"2024","journal-title":"Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pasqualoni, M., Orlandi, A., Palazzo, A., Garufi, G., Cannizzaro, M.C., Pontolillo, L., Pannunzio, S., Cutigni, C., Sollena, P., and Federico, F. (2023). Case Report: Vitiligo-like Toxicity Due to Ribociclib during First-Line Treatment of Metastatic Breast Cancer: Two Cases of Premature Interruption of Therapy and Exceptional Response. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1067264"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4\/6 Inhibitors: A Systematic Review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Restrepo, J.C., Mart\u00ednez Guevara, D., Pareja L\u00f3pez, A., Montenegro Palacios, J.F., and Liscano, Y. (2024). Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review. Cancers, 16.","DOI":"10.3390\/cancers16132338"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Due\u00f1as, D., Daza, J., and Liscano, Y. (2023). Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review. Medicina, 59.","DOI":"10.3390\/medicina59071336"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/CCID.S344867","article-title":"Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4\/6 Inhibitor: A Case Report and Literature Review","volume":"15","author":"Sharaf","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"T\u00fcrkel, A., Kara\u00e7in, C., \u00d6ner, \u0130., \u015eeyran, E., and \u00d6ks\u00fczo\u011flu, B. (2023). Vitiligo-like Lesions Associated with Ribociclib in a Woman with Metastatic Breast Cancer. J. Oncol. Pharm. Pract., 10781552231156521.","DOI":"10.1177\/10781552231156521"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sammons, S.L., Topping, D.L., and Blackwell, K.L. (2017). HR+, HER2\u2013 Advanced Breast Cancer and CDK4\/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Curr. Cancer Drug Targets, 17.","DOI":"10.2174\/1568009617666170330120452"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Henning, S.W., Jaishankar, D., Barse, L.W., Dellacecca, E.R., Lancki, N., Webb, K., Janusek, L., Mathews, H.L., Price, R.N., and Le Poole, I.C. (2020). The Relationship between Stress and Vitiligo: Evaluating Perceived Stress and Electronic Medical Record Data. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227909"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Anders, C.K., LeBoeuf, N.R., Bashoura, L., Faiz, S.A., Shariff, A.I., and Thomas, A. (2020). What\u2019s the Price? Toxicities of Targeted Therapies in Breast Cancer Care. Am. Soc. Clin. Oncol. Educ. Book, 55\u201370.","DOI":"10.1200\/EDBK_279465"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Silvestre Torner, N., Aguilar Mart\u00ednez, A., Echarri Gonz\u00e1lez, M.J., Tabbara Carrascosa, S., Rom\u00e1n Sainz, J., and Gruber Velasco, F. (2022). Ribociclib-Induced Vitiligo: A Case Report. Dermatol. Pract. Concept., e20220045.","DOI":"10.5826\/dpc.1202a45"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","article-title":"Cutaneous Toxicities Occurring during Palbociclib (CDK4\/6 Inhibitor) and Endocrine Therapy in Patients with Advanced Breast Cancer: A Single-Centre Experience","volume":"188","author":"Chawla","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4\/6 Inhibitor in Various Solid Tumors","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/1078-0432.CCR-15-0390","article-title":"Palbociclib for the Treatment of Estrogen Receptor\u2013Positive, HER2-Negative Metastatic Breast Cancer","volume":"21","author":"Morikawa","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Alikhan, A., Felsten, L.M., Daly, M., and Petronic-Rosic, V. (2011). Vitiligo: A Comprehensive Overview. J. Am. Acad. Dermatol., 65.","DOI":"10.1016\/j.jaad.2010.11.061"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-023-07217-2","article-title":"Multi-Center Retrospective Review of Vitiligo-like Lesions in Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4 and 6 Inhibitors","volume":"204","author":"Bang","year":"2024","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:58Z","timestamp":1760031298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/5\/158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["diseases13050158"],"URL":"https:\/\/doi.org\/10.3390\/diseases13050158","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}